Dyax treats first patient in Phase 2 ecallantide trial
The trial aims to compare the effectiveness and safety of conventional therapy treatment plus ecallantide to conventional therapy treatment plus placebo in 176 patients recruited at 40 US
Gilead Sciences has opened a new 182,000ft² research centre at its Foster City headquarters in California, US, for advancing medicines to treat challenging diseases.